Another experimental Alzheimer’s drug, donanemab, has been found to modestly slow the progression of the disease in patients by about four to seven months, according to researchers. Eli Lilly and Co. is currently seeking approval from the Food and Drug Administration for donanemab, which would make it the second Alzheimer’s treatment shown to delay the disease, following the approval of Leqembi from Eisai. While the drug does not cure Alzheimer’s, researchers believe it offers a meaningful treatment option for patients. Safety concerns include brain swelling and bleeding, as seen in the study conducted by Lilly, which was linked to three deaths. Researchers continue to explore the benefits and risks of these drugs and how they can be best utilized in patient care.
Promising Alzheimer’s Drug Demonstrates Slowed Progression in Patients; U.S. Approval on the Horizon, Anticipated
Denial of responsibility! Swift Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – swifttelecast.com. The content will be deleted within 24 hours.